Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MH002 in mild-to-moderate ulcerative colitis insufficiently controlled with 5-aminosalicylic acid
2025-524682-24-00Phase 2Authorised
- Sponsor
- MRM Health
- Start
- Sep 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing MH002 with Placebo (2 arms). Primary endpoint: Change from baseline in centrally assessed Mayo endoscopic subscore at Week 12. Planned start Sep 2026; status: authorised.
02
Drugs
MH002
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-524682-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524682-24-00.